Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Mersana and Takeda expand partnership to advance development of Fleximer-based ADC therapies

Feb. 4, 2016

Targovax submits a study protocol for ONCOS-102 trial to the regulatory authorities in Spain

Feb. 3, 2016

Elotuzumab receives positive CHMP opinion for the treatment of multiple myeloma

Feb. 1, 2016

Phase III Opdivo trial meets endpoint, stopped early

Jan. 29, 2016

Avax Technologies announces results of its OVAX phase I/II clinical trial

Jan. 29, 2016

Cyramza approved in Europe for NSCLC and colorectal cancer

Jan. 28, 2016

Prima BioMed starts phase I study of IMP-321 for the treatment of melanoma

Jan. 27, 2016

FDA puts Medivation's pidilizumab on clinical hold

Jan. 27, 2016

OncoMed unblinds phase II trial of tarextumab following DSMB analysis

Jan. 26, 2016

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Jan. 25, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...